Speakers
Joe Codamo
Senior Director
Catalent Pharma Solutions
Day 1 – Track C – Afternoon
2:00 pm | Flexible & Innovative Design Considerations for Cell Therapy Processes & Facilities
Patrick Melvin
VP, Clinical Development
Syneos Health
Jane Bentley
VP, Project Management
Syneos Health
Day 1 – Track B – Afternoon
3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials
Sharon Longhurst
VP Development
Gadeta
Day 1 – Track C – Afternoon
3:00 pm | Panel Discussion: Creating the Therapies of Tomorrow with Large Scale Production of Off-the-Shelf Products
Gabriel Gata
PhD, Field Application Scientist Lead
Lonza Personalized Medicine
Hemant Dhamne
Gene & Cell Therapy
Independent Expert
Day 2 - Track C - Morning
10:45 am | Smart Manufacturing Technologies for Cell & Gene Therapy Products
Dian Kortleve
Scientist
Pan Cancer T
Day 1 – Track A – Evening
5:30 pm | Identification & Testing of Novel Cancer-Restricted Targets & Their TCRS to Develop Safe & Effective T-Cell Treatment
Elie Haddad
Professor, Department of Pediatrics
University of Montreal
Focus Day - Track B - Morning
10:30 am | CAR Therapy Beyond T-Cells: CAR-NK Cells or Even CAR In Stem Cells for Cancer Immunotherapy?
John Rossi
Senior Vice President, Translational Medicines & Research
CERo Therapeutics
Day 1 – Track A – Afternoon
3:00 pm | Panel Discussion: Changing the Face of Cell Therapies with In Vivo Gene Engineering
Day One
Tuesday 25th February 2020
9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches
Day Two
Wednesday 26th February 2020
8:15 am | Development & Functional Characterisation of Chimeric Engulfment Receptor (CER) T-Cells for the Treatment of Hematologic & Solid Malignancies
Reagan Jarvis
Chief Executive Officer
Anocca
Day 1 – Track A – Evening
4:30 pm | Integrated Target Discovery & TCR Generation Pipelines for TCR-Modified Cell Therapies
Maurizio Chiriva Internati
President, Chief Executive Officer, Chairman & Founder
Kiromic BioPharma
Benjamin Rengstl
Director Immunoreceptor Therapy & Medical Expert Clinical Development
BioNTech Cell & Gene Therapies & BioNTech SE
Workshop – Track B – Afternoon
12:00 pm | Workshop E: BNT211: A Phase 1/11 Trial to Evaluate Safety & Efficacy of CLDN6 CAR-T & CARVas Based In Vivo Expansion to Improve Treatment of Patients with CLDN6+ Advanced Solid Tumours
Giulia Casorati
Head of Experimental Immunology Unit
San Raffaele Scientific Institute
Day One
Tuesday 25th February 2020
8:30 am | Antigen-Specific Targeting of Tumours Across MHC Barriers
Workshop - Track A - Evening
3:00 pm | Workshop C: Antigen-Specific Targeting of Tumours Across MHC Barriers
Emily Titus
Vice President, Process Sciences
Notch Therapeutics
Christopher Baldwin
Chain Director, Cell & Gene Therapy
GSK
Day 1 – Track C – Morning
11:00 am | Paving the Future of Supply Chain & Logistics with Digitalisation & Automation
Leah Sibener
Co-Founder, Head of Therapeutic Discovery
3T Biosciences
Workshop – Track B – Evening
3:00 pm | Workshop F: Supercharging Development of Innovative Platforms for Identification & Validation of Novel Targets Beyond CD19
Kate Rochlin
Chief Operating Officer
IN8bio
Day Two
Wednesday 26th February 2020
5:30 pm | Chair’s Closing Remarks
4:45 pm | Novel Gamma-Delta CAR-T approaches for systemic delivery in Solid Tumors
Laura Pierce
Biomedical Engineer
NIST
Workshop – Track C – Afternoon
12:00 pm | Workshop H: Advancing Measurement Methods to Improve Confidence in Characterising CTPs
Richard Boyd
Chief Scientific Officer
Cartherics
Focus Day - Track B - Morning
10:00 am | iPSC - A Uniquely Renewable Source of CAR-NK Cells
Nicholas Boyd
Chief Technology Officer
Cartherics
Day 2 - Track C - Evening
3:45 pm | Allogenic Solid Tumor Immunotherapy using iPSCDerived Gene-Edited iNK Cells
Eric Von Hofe
Chief Executive Officer
AffyImmune
Stanley Frankel
Chief Medical Officer
Cytovia
Day 2 - Track C - Afternoon
1:45 pm | Exploring the Potential of Combining Engineered iPSC NK Cells with NK cell Engagers and the Future of Cell Therapies
Focus Day - Track B - Afternoon
12:00 pm | Exploring the Potential of Combining Engineered iPSC NK Cells with NK cell Engagers & the Future of Cell Therapies
Mythili Koneru
Chief Medical Officer
Marker Therapeutics
Day Two
Wednesday 26th February 2020
8:45 am | Allogeneic Multi-Tumour-Associated Antigen-Specific T-Cell Therapy
Mubin Tarannum
Post-Doctoral Researcher
Dana-Farber Cancer Institute
Day 2 - Track C - Evening
4:15 pm | Memory-Like NK Cell CARs for Mesothelin Expressing Solid Tumours
Focus Day - Track B - Evening
1:30 pm | Memory-Like NK Cell CARs for Mesothelin Expressing Solid Tumours
Michael Kchlinsky
Co-Founder
Carisma Therapeutics
Focus Day - Track B - Evening
2:30 pm | Development of CT-0508, a First-in-Class CAR-M, for Solid Tumour Immunotherapy
Qasim Rafiq
Senior Lecturer & Associate Professor - Cell & Gene Therapy Bioprocessing
University College London
Day 1 – Track C – Afternoon
3:00 pm | Panel Discussion: Creating the Therapies of Tomorrow with Large Scale Production of Off-the-Shelf Products
1:30 pm | Process Intensification and Scalable Manufacturing Strategies for CAR-T Production
Marko Radic
Associate Professor
The University of Tennessee Health Science Center
Focus Day - Track A - Evening
1:30 pm | Roads to Cell Therapy in Autoimmune Diseases
Scott Kitchen
Director & Associate Professor – Medicine
UCLA
Day 2 - Track B - Evening
4:15 pm | Engineering TCR & CAR-T Cells Through Hematopoietic Stem Cells
Focus Day - Track A - Afternoon
12:00 pm | Engineering TCR & CAR-T Cells Through Hematopoietic Stem Cells
Maja Buerdek
Director Translational Medicine
Medigene
John Maher
Chief Scientific Officer
Leucid Bio
Day 1 - Track A - Morning
12:00 pm | CAR-T Cell Immunotherapy of Solid Tumours: Parallel Learning from the Clinic & Lab
Chris Bond
Senior Vice President Preclinical & Translational Sciences
Notch Therapeutics
Cedrik Britten
Chief Medical Officer
Immatics
Day 1 – Track B – Morning
11:00 am | Driving Clinical Activity of TCR-T Cells in the Challenging Solid Tumour Setting
Day One
Tuesday 25th February 2020
9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches
Peter Olagunju
Chief Technical Officer
TCR2 Therapeutics
Hong Ma
Senior Vice President, Clinical Development
CARsgen Therapeutics
Maria Castellà
Research Associate, Immunotherapy Unit
Hospital Clinic de Barcelona
Rajiv Khanna
Professor, Senior Scientist, Head Department of Immunology
QIMR Berghofer Medical Research Institute
Focus Day - Track A - Evening
2:30 pm | “Off-the-Shelf” Allogeneic CAR & TCR Cell Therapies for Virus-Associated Diseases
David Fontana
Chief Business & Strategy Officer
Umoja BioPharma
Day 1 – Track A – Afternoon
3:00 pm | Panel Discussion: Changing the Face of Cell Therapies with In Vivo Gene Engineering
2:30 pm | Attacking Solid Tumours with an Integrated Approach of Universal Tumour Tags & In Vivo Transduced CARs
Hannes Iserentant
Senior Director R&D and IP
Celyad
Day 1 – Track C – Afternoon
3:00 pm | Panel Discussion: Creating the Therapies of Tomorrow with Large Scale Production of Off-the-Shelf Products
2:30 pm | Building on Non-Gene Edited Approaches to Develop Allogeneic, Off-The-Shelf CAR-T Cells
Roddy O’Connor
Research Assistant Professor
Center for Cellular Immunotherapies, UPenn School of Medicine
Day 2 - Track A - Afternoon
Yihong Yao
Chief Scientific Officer
CBMG
Jak Knowles
Chief Executive Officer
Affini-T Therapeutics
Workshop - Track A - Afternoon
12:00 pm | Workshop B: Armouring T-Cells to Overcome the Tumour Microenvironment for TCR Therapies in Solid Tumours
Ali Mohamed
Vice President of CMC
Immatics
Day 1 – Track C – Evening
6:00 pm | Roundtable Discussion- Manufacturing Innovations to Improve Robustness of T cell Therapies
Day 2 - Track C - Morning
11:45 am | Developing Next-Generation TCR-T Therapies by CD8 Co-Expression
Workshop - Track C - Morning
9:00 am | Workshop G: Manufacturing Innovations to Improve Robustness of T-Cell Therapies
Lawrence Lamb
Chief Scientific Officer
IN8bio
Day 2 - Track B - Morning
10:45 am | Maintaining Both Innate Killing & Specific Targeting of Heterogeneous Tumours with Chemotherapy-Resistant Chlorotoxin CAR-T Cells
Day Two
Wednesday 26th February 2020
8:05 am | Chair’s Opening Remarks
Blake Aftab
Chief Scientific Officer
Adicet Bio
Day 1 – Track B – Evening
6:00 pm | Driving Development of Allogeneic Cell Therapies and CAR-T with Novel Signalling Technologies
Marc Martinez-Llordella
Founder & Vice President Biology
Quell Therapeutics
Day 2 - Track B - Evening
3:45 pm | Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic
Focus Day - Track A - Afternoon
11:30 am | Use of Engineered Regulatory T-Cells to Induce Immunologic Tolerance: Path to the Clinic
Haig Aghajanian
Vice President of Research
Capstan Therapeutics
Focus Day - Track A - Morning
10:30 am | CAR-T Cell Therapy for the Treatment of Fibrotic Conditions
Workshop - Track A - Morning
9:00 am | Workshop A: In Vivo Production of Functional CAR-T Cells by mRNA Targeted Lipid Nanoparticles
Sylvain Simon
Postdoctoral Fellow
Fred Hutchinson Cancer Research Center
Rudy Gonzalez
Executive Director of Stem Cell Therapeutics
Caribou Biosciences
Day 2 - Track C - Afternoon
2:15 pm | Induced Pluripotent Stem Cell-Derived Natural Killer Cells for the Treatment of Solid Tumours
Focus Day - Track B - Afternoon
11:30 am | Induced Pluripotent Stem Cell-Derived Natural Killer Cells for the Treatment of Solid Tumours
Steven Kanner
Chief Scientific Officer
Caribou Biosciences
Day 1 – Track B – Afternoon
2:30 pm | Next Generation Allogeneic CAR-T Cell Therapies for Hematologic Malignancies
Day 1 – Track B – Evening
4:30 pm | Roundtable Discussion: Exploring Safety, Function and Potency of Allogeneic CAR-T Cells
Jan Davidson-Moncada
Chief Medical Officer
Wugen
Day 2 - Track B - Afternoon
2:45 pm | A Phase 1/2 Dose-Escalation & Dose-Expansion Study of the Safety & Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / Acute Lymphoblastic Lymphoma (LBL)
Remus Vezan
Chief Medical Officer
CERo Therapeutics
Lucia Mori
Founding Chief Scientific Officer
Matterhorn Biosciences
Day One
Tuesday 25th February 2020
8:30 am | Antigen-Specific Targeting of Tumours Across MHC Barriers
Workshop - Track A - Evening
3:00 pm | Workshop C: Antigen-Specific Targeting of Tumours Across MHC Barriers
Vijay Reddy Peddareddigari
Chief Research & Development Officer
Tmunity Therapeutics
Day 1 – Track B – Afternoon
1:30 pm | Overcoming CAR-T Toxicity with Next Generation T-Cell Reprogramming
Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics
Day 1 - Track A - Morning
11:00 am | A Next Generation TCR & Epitope Discovery Platform for the Development of Engineered TCR Therapies for Solid Tumours
Day One
Tuesday 25th February 2020
9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches
8:20 am | Chair’s Opening Remarks
Tina Albertson
Chief Medical Officer, Head of Development
Lyell Immunopharma
Day 1 – Track C – Evening
5:30 pm | Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours
Workshop – Track C – Evening
3:00 pm | Workshop I: Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours
Namir Hassan
Chief Executive Officer
Zelluna Immunotherapy
Day 2 - Track A - Morning
10:45 am | TCR-NK: A Novel Treatment Paradigm For The Treatment of Solid Cancer
Pascal Touchon
President & Chief Executive Officer
Atara Biotherapeutics
Focus Day - Track A - Morning
10:00 am | Allogeneic vs Autologous Cell Therapies: CAR-T & Beyond
Nicholas Clarkson
Vice President and Head of Platform Research
Oxford Biomedica
Day 2 - Track C - Morning
12:15 pm | Advances in Lentiviral Technology and Manufacturing Processes
Emily Wilkinson
Adoptive Cell Lead Research Analyst
Beacon
Day 2 - Track B - Morning
11:15 am | A Landscape Overview of CAR-T Cell Therapy
Justyna Ogonek
Senior Scientist
Medigene
Day 1 – Track A – Evening
6:00 pm | Identifying Peptide Targets for TCR-Ts Derived from Non-Coding RNA Sequences
Ali Shariat
Senior Director, Business Development
Syneos Health
Rayna Patel
Co-Founder & CEO
Vinehealth
Dr Rayna Patel is a medical doctor & neuroscientist with an MPhil in Translational Medicine. She has extensive experience in academia (Cambridge, Harvard, MIT, Columbia) and was an Associate Fellow of Clare Hall College, Cambridge. Rayna has subsequently held strategic & commercial roles in government policy, tech startups & the Cabinet Office’s Nudge Unit, where she used behavioural science to rewire patient behaviours through digital products. She is currently CEO and Co-Founder of Vinehealth, a digital platform using a combination of behavioural science and AI to improve the quality of life and survival of cancer patients, whilst generating crucial real-world data to better inform healthcare delivery and drug development.
Day 1 – Track B – Afternoon
3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials
Houria Bachtarzi
Associate Director, Regulatory - Gene and Cell Therapies
ProPharma Group
Day 1 – Track B – Evening
5:00 pm | Navigating the Challenges and Safety Considerations for Next-Generation Cell Therapies
Taylor Jensen, PhD
VP, Head of Labcorp Oncology
Labcorp Oncology
Payal Roychoudhury, PhD, MBA
Field Application Specialist, Central Europe
ScaleReady
Mark Harris
Senior Scientist
Autolus
Day 1 – Track C – Morning
12:00 pm | Autologous CAR-T Cell Automation and Certification Time
Sara Padrell
Business Development Director
Akron Bio
Day 1 – Track C – Morning
11:30 am | Akron’s New Line of Closed System Solutions™ & the Production of Next Generation Cell-Based Immunotherapies
Robert Newman
Chief Scientific Officer
FUJIFILM Irvine Scientific
Day 1 – Track A – Afternoon
2:00 pm | 3 Key Factors in Cell Cryopreservation that Impact the Manufacturability of Cell & Gene Therapies
Peter Djali
Manager, Cell Avidity/Immuno-Oncology Division
LUMICKS
Day 1 - Track A - Morning
11:30 am | Tumour-Effector Cell Avidity is a Key Driver for Cellular Therapy Efficacy
Luca Gattinoni
Professor, Chair for Functional Immune Cell Modulation
Leibniz Institute for Immunotherapy
Day 1 – Track A – Evening
5:00 pm | Reprogramming T Cell Fate and Antitumor Function by MicroRNA Therapeutics
Toni Cathomen
Professor of Cell and Gene Therapy, Director, Institute for Transfusion Medicine and Gene Therapy,Scientific Director, Center for Chronic Immunodeficiency
University of Freiburg
Day 1 – Track C – Evening
5:00 pm | Advances in Non-Viral T-Cell Engineering in Clinical Manufacturing
Mark Throsby
COO, CSO
Gadeta
Day 2 - Track A - Morning
11:45 am | Harnessing Natural gd T-cell Receptors (gd TCR) to Develop Effective Cellular Therapies for Solid Tumors
Brian Philip
Associate Director of Allogeneic Therapy
Triumvira Immunologics Inc
Day 2 - Track B - Afternoon
1:45 pm | Making Solid Tumour Immunotherapy Safer and More Accessible
Rudy Gonzalez
Executive Director of Stem Cell Therapeutics
Caribou Biosciences
Amanda Trent
PhD, Director of Assay Development
Accellix
Day 2 - Track C - Morning
11:15 am | Standardizing in-process QC with the Accellix Automated Flow Cytometry Platform.
Lynn Donald
Senior Project Director
Syneos Health , Novel and Emerging Therapies, Oncology
Day 1 – Track B – Afternoon
3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials
Sophie Papa
Chief Medical Officer
Enara Bio
Day 1 – Track B – Afternoon
3:00 pm | Next-Gen Cell Therapies- Listening and Engaging with Patient Perspectives as an Essential Element in Clinical Trials
Marvin Gee
VP of Target Discovery, Co-Founder
3T Biosciences
Day 2 - Track A - Evening
3:45 pm | Supercharging Development of Innovative Platforms for Identification and Validation of Novel Targets Beyond CD19
Natalia Denisova, MD, PhD
VP, Head of Medical Affairs
MphaR
Certified oncologist, experienced Medical Affairs professional with more than 15 years in Pharmaceutical Industry with a demonstrated history of preparation and leading successful launch in Oncology/OncoHematology and other therapeutic areas. Was leading international teams across more than 70 countries WW. In her current role Natalia provides the leadership to MphaR Clinical development team to support clinical trials in the most efficient way.
Day 1 – Track B – Afternoon
2:00 pm | How to Overcome the Recruitment Challenges in CAR-T cell Clinical Trials
Aaron K. Sato, Ph.D.
Chief Scientific Officer
Twist Bioscience
Day 2 - Track A - Morning
11:15 am | Writing the Future of Cell Therapies using the Twist Biopharma Library of Libraries
Chris Herring
VP Head of Discovery Research,
Adaptimmune
Day 2 - Track B - Afternoon
2:15 pm | Leveraging Clinical and Translational Insights from Next Generation SPEAR T-cells: Building a MAGE A4 T-Cell Therapy Franchise
Terry Fry
Senior Vice President, Head of T Cell Therapeutics
Sana Biotechnology, Inc.Institute
Day One
Tuesday 25th February 2020
9:30 am | Hypoimmune & In Vivo Delivery Platforms to Enable Off-The-Shelf CAR-T Cell Therapies
Peter Djali
Manager, Cell Avidity/Immuno-Oncology Division
Lumicks
Marco Rotondi
Project Leader – Process Development
Cellectis
Jakob Dupont
Executive Vice President, Head of Global Research & Development
Atara Biotherapeutics
Day 1 – Track B – Evening
5:30 pm | Accelerating Clinical Development of Off-the-Shelf Cell Therapy for Liquid and Solid Tumours
Melanie Rietenbach
Global Product Manager Immunology Engineered Cells
Miltenyi
Geoff Hodge
Chief Executive Officer
SOTIO US
Day 2 - Track A - Afternoon
1:45 pm | BOXR: A Platform for Improving T-Cell Performance in the Solid Tumour Microenvironment
Simone Steiner
Head, Technical Development and Manufacturing
Tigen Pharma
Day Two
Wednesday 26th February 2020
9:15 am | How to Overcome Apheresis Products Variability in Cell and Gene Therapy Manufacturing: Best Practices in Optimizing Cell Collection
Sara Lewandowski
Data Services Manager
Terumo Blood and Cell Technologies
Day Two
Wednesday 26th February 2020
9:15 am | How to Overcome Apheresis Products Variability in Cell and Gene Therapy Manufacturing: Best Practices in Optimizing Cell Collection
Mourad Ferhat
EMEA Product Manager
Isoplexis
Dr Richard Harbottle
Head of DNA Vector Research
German Cancer Research Centre (DKFZ)
Day 1 – Track B – Morning
11:30 am | Next-Generation DNA NanoVectors - An Alternative Vector Platform for the Safe, Rapid, and Persistent Manufacture of Recombinant T cells for Autologous T Cell Immunotherapy
Christopher Heery
Chief Medical Officer
Arcellx
Day 2 - Track B - Morning
11:45 am | ARC-sparX : A Modular & Universal Cell Platform
Cécile Bauche
Chief Scientific Officer
Ixaka
Day 1 – Track A – Afternoon
3:00 pm | Panel Discussion: Changing the Face of Cell Therapies with In Vivo Gene Engineering
1:30 pm | A Nanotechnology-Based In Vivo Gene Delivery Platform Allowing the In Vivo Targeting & Transduction of T-Cells for Haematological Malignancies & Beyond
Day 1 – Track C – Evening
4:30 pm | Bioproduction Challenges to Bring In Vivo Car-T into the Clinic
Hinrich Abken
Regensburg University
RCI Regensburg Center for Interventional Immunology
Samantha O’Hara
Allogeneic Research Lead
Umoja Biopharma
Day 2 - Track C - Afternoon
Dolores J. Schendel
Chief Executive Officer & Chief Scientific Officer
Medigene AG
Sven Killi
Chief Executive Officer
Antion Biosciences SA
Day 2 - Track A - Afternoon
2:45 pm | Multiplex Gene Engineering with miCAR – Moving Beyond Editing to Create Next Generation Allogeneic Cell Therapies
Adrian Bot, MD, PhD
Chief Scientific Officer and Executive Vice President, R&D
Capstan Therapeutics
Day One
Tuesday 25th February 2020
9:00 am | Industry Leaders’ Fireside Chat - Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches
Day Two
Wednesday 26th February 2020